- Home
- CHRS vs LGI Comparison
CHRS vs LGI Comparison
Compare CHRS & LGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- LGI
- Stock Information
- Founded
- CHRS 2010
- LGI 2004
- Country
- CHRS United States
- LGI United States
- Employees
- CHRS N/A
- LGI N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- LGI
- Sector
- CHRS Health Care
- LGI
- Exchange
- CHRS Nasdaq
- LGI Nasdaq
- Market Cap
- CHRS 191.3M
- LGI 210.3M
- IPO Year
- CHRS 2014
- LGI N/A
- Fundamental
- Price
- CHRS $1.32
- LGI $16.29
- Analyst Decision
- CHRS Strong Buy
- LGI
- Analyst Count
- CHRS 4
- LGI 0
- Target Price
- CHRS $5.38
- LGI N/A
- AVG Volume (30 Days)
- CHRS 2.0M
- LGI 41.1K
- Earning Date
- CHRS 03-12-2025
- LGI 01-01-0001
- Dividend Yield
- CHRS N/A
- LGI 7.10%
- EPS Growth
- CHRS N/A
- LGI N/A
- EPS
- CHRS N/A
- LGI N/A
- Revenue
- CHRS $304,340,000.00
- LGI N/A
- Revenue This Year
- CHRS $2.47
- LGI N/A
- Revenue Next Year
- CHRS N/A
- LGI N/A
- P/E Ratio
- CHRS N/A
- LGI N/A
- Revenue Growth
- CHRS 44.19
- LGI N/A
- 52 Week Low
- CHRS $0.66
- LGI $12.66
- 52 Week High
- CHRS $2.87
- LGI $16.68
- Technical
- Relative Strength Index (RSI)
- CHRS 41.91
- LGI 53.60
- Support Level
- CHRS $1.38
- LGI $15.59
- Resistance Level
- CHRS $1.60
- LGI $16.32
- Average True Range (ATR)
- CHRS 0.12
- LGI 0.20
- MACD
- CHRS -0.03
- LGI 0.05
- Stochastic Oscillator
- CHRS 1.10
- LGI 95.89
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About LGI Lazard Global Total Return and Income Fund
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt, and others.